Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ...

Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain ...

Galapagos' CAR-T therapy GLPG5101 shows promise but faces challenges with limited data, cash reserves, and competition in the ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

Largest Real-World Evidence (RWE) Analysis of Yescarta in Second-Line Shows 71% Overall Survival Rate, Consistent with Pivotal ZUMA-7 Study, in Broader Patient Population with Relapsed/Refractory ...

Therefore, it is similar in principle to the approved CAR T-cell therapies used in cancer therapy, such as Kymriah and ...

Kite, a Gilead Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory no ...

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

The company states: “Kite, a Gilead (GILD) Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory non-Hodgkin ...